Atrovent 20micrograms/dose inhaler CFC free

Riik: Suurbritannia

keel: inglise

Allikas: MHRA (Medicines & Healthcare Products Regulatory Agency)

Toimeaine:

Ipratropium bromide

Saadav alates:

Boehringer Ingelheim Ltd

ATC kood:

R03BB01

INN (Rahvusvaheline Nimetus):

Ipratropium bromide

Annus:

20microgram/1dose

Ravimvorm:

Pressurised inhalation

Manustamisviis:

Inhalation

Klass:

No Controlled Drug Status

Retsepti tüüp:

Valid as a prescribable product

Toote kokkuvõte:

BNF: 03010200; GTIN: 5012816066007

Infovoldik

PACKAGE LEAFLET: INFORMATION FOR THE USER
ATROVENT
® INHALER CFC-FREE
20 MICROGRAMS/ACTUATION
PRESSURISED INHALATION
SOLUTION
(ipratropium bromide)
• Keep this leaflet. You may need to read it again.
• If you have any further questions, ask your doctor or
pharmacist.
• This medicine has been prescribed for you. Do not pass it
on to others. It may harm them, even if their symptoms
are the same as yours.
• If any of the side effects gets troublesome or serious, or if
you notice any side effects not listed in this leaflet, please
tell your doctor or pharmacist.
IN THIS LEAFLET:
1. What ATROVENT Inhaler CFC-FREE is and what it is used for
2. Before you use ATROVENT Inhaler CFC-FREE
3. How to use ATROVENT Inhaler CFC-FREE
4. Possible side effects
5. How to store ATROVENT Inhaler CFC-FREE
6. Further information
1. WHAT ATROVENT INHALER CFC-FREE IS AND WHAT IT IS USED FOR
The name of your medicine is ATROVENT Inhaler CFC-FREE.
This is an inhaler and contains a medicine called
ipratropium bromide. This belongs to a group of medicines
called anticholinergics which act as bronchodilators. It is
used to make breathing easier for people with asthma or
‘chronic obstructive pulmonary disease’ (COPD), often
referred to as chronic bronchitis. You may have difficulty
breathing, shortness of breath, wheezing or tightness in
your chest.
ATROVENT works by opening up your airways.
2. BEFORE YOU USE ATROVENT INHALER CFC-FREE
DO NOT USE ATROVENT IF:
• You are allergic (hypersensitive) to ipratropium or any of
the other ingredients in ATROVENT. (Listed in section 6:
Further information)
• You are allergic to similar medicines which contain
atropine or medicines like atropine
• You are pregnant, think you are pregnant, likely to get
pregnant or are breast-feeding
Do not use if any of the above apply to you. If you are not
sure, talk to your doctor or pharmacist before using
ATROVENT.
TAKE SPECIAL CARE WITH ATROVENT
Check with your doctor or pharmacist before using this
medicine if:
• You have glaucoma, or have been t

Toote omadused

OBJECT 1
ATROVENT INHALER CFC-FREE
Summary of Product Characteristics Updated 01-Mar-2018 | Boehringer
Ingelheim Limited
1. Name of the medicinal product
ATROVENT Inhaler CFC-Free 20 micrograms/actuation pressurised
inhalation solution.
2. Qualitative and quantitative composition
One metered dose (ex-valve) contains 20 micrograms ipratropium bromide
(as the monohydrate).
For excipients, see 6.1.
3. Pharmaceutical form
Pressurised inhalation, solution.
Each container is filled with 10 ml of a clear, colourless liquid,
free from suspended particles.
4. Clinical particulars
4.1 Therapeutic indications
ATROVENT Inhaler CFC-Free is indicated for the regular treatment of
reversible bronchospasm
associated with chronic obstructive pulmonary disease (COPD) and
chronic asthma.
4.2 Posology and method of administration
For inhalation use.
Adults (including the elderly):
Usually 1 or 2 puffs three or four times daily, although some patients
may need up to 4 puffs at a time to
obtain maximum benefit during early treatment.
Children:
6-12 years of age:
Usually 1 or 2 puffs three times daily.
< 6 years of age:
Usually 1 puff three times daily.
In order to ensure that the inhaler is used correctly, administration
should be supervised by an adult.
The recommended dose should not be exceeded.
If therapy does not produce a significant improvement, if the
patient's condition gets worse or if a reduced
response to treatment becomes apparent, medical advice must be sought.
The patient should be instructed
that in the case of acute or rapidly worsening dyspnoea a physician
should be consulted immediately.
ADMINISTRATION
The correct administration of ipratropium bromide from the inhaler is
essential for successful therapy. For
detailed information on instructions for use please refer to the
Patient Information Leaflet.
The canister should be pressed twice to release two metered doses into
the air before the inhaler is used
for the first time, or when the inhaler has not been used for 3 days
or more, to ensure that the inhaler is
workin